Daniela Rutigliano
Overview
Explore the profile of Daniela Rutigliano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blandino G, Satchi-Fainaro R, Tinhofer I, Tonon G, Heilshorn S, Kwon Y, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):334.
PMID: 39731178
On September 23-24 (2024) the 6th Workshop IRE on Translational Oncology, titled "Cancer Organoids as Reliable Disease Models to Drive Clinical Development of Novel Therapies," took place at the IRCCS...
2.
Canu V, Vaccarella S, Sacconi A, Pulito C, Goeman F, Pallocca M, et al.
Cell Death Dis
. 2024 Aug;
15(8):603.
PMID: 39164278
Triple negative breast cancer (TNBC) is an aggressive disease which currently has no effective therapeutic targets and prominent biomarkers. The Sperm Associated antigen 5 (SPAG5) is a mitotic spindle associated...
3.
Cioce M, Fumagalli M, Donzelli S, Goeman F, Canu V, Rutigliano D, et al.
J Exp Clin Cancer Res
. 2023 Jul;
42(1):170.
PMID: 37460938
Background: Approximately 20-50% of patients presenting with localized colorectal cancer progress to stage IV metastatic disease (mCRC) following initial treatment and this is a major prognostic determinant. Here, we have...
4.
Cioce M, Marra A, Rutigliano D, Fazio V
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370791
It is increasingly clear that Intratumor heterogeneity (ITH) fuels tumor evolution, matching the concept of cancer as a heterogeneous ecosystem of spatially and temporally modulated cell subpopulations, which exploits dynamic...
5.
Cioce M, Rutigliano D, Puglielli A, Fazio V
Cancer Drug Resist
. 2022 Sep;
5(3):814-828.
PMID: 36176750
Malignant pleural mesothelioma is a chemoresistant tumor, and biphasic and sarcomatoid histologies portend the worst prognosis for malignant pleural mesothelioma (MPM) patients. We obtained the microRNA expression profile of three...